Studies About Thyroid Function And Metabolic Syndrome Components In Type2Diabetes Mellitus Patients With Non-alcoholic Fatty Liver Disease

Objective: To analyze the changes in thyroid function, metabolicsyndrome (MS) component indicators related to blood in type2diabetesmellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD). Toexplore the relationship between NAFLD and thyroid hormone (TH) and theMS.Methods: In T2DM patients, by history,color Doppler ultrasound screeningfor liver function indicators, patients were included in the NAFLD group andthe non-NAFLD group, each with100cases. All selected objects are collectedgeneral information such as gender, age, blood pressure, height, weight, BMI,measured thyroid function five (TT3, TT4, FT3, FT4, TSH), FBG, FINS, FC-P,HbA1c, lipids, liver function, UA, HCY, blood clotting and so on. Data analysiswas done by the statistics software SPSS16.0with two-sample t test, Spearmancorrelation analysis and Logistic regression analysis.Results:1. In T2DM patients,compared with the non-NAFLD group,NAFLD patients had heavier weight〔（69.68±13.06）/(59.58±9.45)kg〕, higherBMI〔(26.50±3.41)/(23.19±3.10)kg/㎡〕, higher diastolic blood pressure （DBP）〔(82.24±11.48)/(78.40±9.81)mmHg〕（P＜0.05）.2. In T2DM patients, compared with the non-NAFLD group, NAFLDpatients had higher T-CHO levels〔(5.18±1.31)/(4.66±1.49)mmol/L〕，higherTG levels〔(3.23±1.24)/(1.67±0.95)mmol/L〕, higher LDL-C levels〔(3.05±0.97)/(2.70±1.10)mmol/L〕, higher Apo-B levels〔(1.14±0.39)/(0.95±0.30)mmol/L〕（P＜0.05）.3. In T2DM patients, compared with the non-NAFLD group, NAFLDpatients had higher ALT levels〔(28.19±18.96)/(22.94±18.00)U/L〕，higherGGT levels lg (GGT)〔(1.52±0.28)/(1.43±0.39)〕，higher ALP levels〔(96.68±29.49)/(78.25±33.21) mmol/L〕, higher UAlevels〔(371.63±72.18)/(318.99±88.42)umol/L〕, higher HCY levels〔(13.05±4.24)/(11.35±4.42)umol/L〕，shorter PT〔(9.66±0.68)/(9.97±1.29)s〕（P＜0.05）.4. In T2DM patients, compared with the non-NAFLD group, NAFLDpatients had higher HbA1c levels〔(9.39±2.10)/(8.47±2.54)%〕，higher FINSlevels lg(FINS)〔(1.76±0.27)/(1.63±0.32)〕, more pronounced IR (Homa-IR)〔(23.82±18.24)/(17.43±12.63)〕（P＜0.05）.5. In T2DM patients, compared with the non-NAFLD group, NAFLDpatients had lower TT3levels〔(1.67±0.36)/(1.80±0.38)nmo1/L〕, lower TT4levels〔(97.62±22.69)/(104.2±18.68)nmo1/L〕（P＜0.05）. FT4levels tendedto decrease〔(10.67±2.15)/(10.99±2.10)pmo1/L〕（P＞0.05）.6. Spearman correlation analysis showed: in T2DM patients, there werenegative correlation between NAFLD and PT, TT4, TT3（P＜0.05）. There werepositive correlation between NAFLD and weight, TG, BMI, UA, ALP, HbA1c,GGT, Apol-B, ALT, Homa-IR, T-CHO, LDL-C, DBP, HCY, FINS, AST, FC-P（P＜0.05）.7. Logistic regression analysis showed: in T2DM patients, risk factors for NAFLD（P＜0.05）were TT3, TG, LDL-C, ALP, HbA1c and UA, which TT3(B=-2.210, OR=0.110) was a protective factor，TG (B=0.728, OR=2.071),LDL-C (B=1.811, OR=6.114), HbA1c (B=0.376, OR=1.457), UA (B=0.010, OR=1.010), ALP (B=0.026, OR=1.027) were risk factors.8. Logistic regression analysis showed that: Compared with the lowLDL-C levels, T2DM patients who had higher LDL-C levels had higher risk ofNAFLD.9. Logistic regression analysis showed that: Compared with the low TT3levels, T2DM patients who had high TT3levels had less risk of NAFLD.Conclusions: In T2DM patients, compared with the non-NAFLD group,NAFLD patients had lower TT3, TT4levels, higher blood lipid, liver enzyme,UA, blood sugar and indicators of cardiovascular disease levels, morepronounced IR. There were negative correlation between NAFLD and TT4, TT3,which TT3may was a protective factor. There were positive correlation betweenNAFLD and blood lipid, liver enzyme, UA, blood sugar, indicators ofcardiovascular disease, which TG, LDL-C, HbA1c, UA, ALP may were riskfactors.